GlassScriptPhysician profile
Greg R Ehgartner
NPI 1346230158
$14,230.88
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $1,636 · 2021: $3,150 · 2022: $3,280 · 2023: $3,167 · 2024: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,665.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,880.85 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,636.07 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,320.98 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,215.98 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $913.35 | 2019-2024 | Xifaxan |
| Amgen INC. | $893.72 | 2019-2024 | Evenity, Prolia, Repatha |
| Pfizer INC. | $874.96 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $597.89 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.96 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Amarin Pharma, INC. | $437.40 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $342.72 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $294.42 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Janssen Pharmaceuticals, INC | $245.32 | 2020-2024 | Xarelto |
| Abbott Laboratories | $224.34 | 2021-2024 | Freestyle Libre, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $214.68 | 2019-2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Ehgartner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.